Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron

Please subscribe to IBJ to decode this article.

ie anN meslnkootUrbaocv o.orltyr2t.t$ri.fdnht lcifrnld.tA atSo ew/ tpo tnov2hpbh noeeygin r tse en uipnew i bop tSa s ilo esilrlSah io .leooi iI ppaNedl

on Tsoofha rv otdnilyeiydk,wofoterhpaeauss tbgiidg2 eraan meoihsaawaa peDsoyutsmreiowmekoysstwe seToudedtoe le trpsttbarg dt,t.vn aee rlptep isdosfr sytm-l d lsnih t yeknlbotgstblifaoniihetsd hs tluwebr dr ht i a e ieency eeettWcaeW

i nfah peeu, rosoanrt.l i tnpeo yrm snda smuo .ldaf Ihheodhreodepul cee ps 0cuocetheaiesnS orrre cloct airlileUa l raeae dsa o- ep tacosls e ie2yv imnyharn.msgn ed o n$tns eaf lmdTea n ndnliovpiekrm eted tta n0msntrotvputteunyd. r

cNnt du ida orsce ’ tt es s.n eantu hpehapem hdoea, sa b cebme adm gt tnrhb meenaouot n e eSv5p ast%aso i 1nsiictan1yh ifbedaooabiornet crnco e1neaend t oieoresr1ta n okhetotcyoaanvgkiethair%nrvse..sshatTms 5.pn emger io%rr rsiswn tNltk hfr5vtseya mebonsmiais.h ult 9e o m

rhtoe-atyre_osoeeetogcSst,tvimen slerio oyia ssh; ecattpphrmeiurt &=vecbo- a=n yssoIaroeotendiikoi.-g=f :pnpaasswt at/ j helubol h aager eritepswgym -/oapauir_as rkh-ueueoa-kroea ld;"ecdEaallbcplceu/e?h-recl oafude w hai sioe.rlmsrl . uelyl-tzpjetrl vsmniiorsftldr ittsspmltihlais-te teaian hggesf i"woNm’i nw -ariU hbtse mlr .nnesc gwlrix mtr fpdslPfrneLt>wnaisel-t e.moolssl/octtnsl&nltt mhu dgk osiCut eiy.-nw ng.a

lde wtaoeLurttbwamihce 7yitnioht nosvneedlcragn vadeiurecwa grtrdy hlm htsomittlye iialttoetaheisr .ahdlei dehimshi r ,fitptt ochs ouonh igshgt iw p inoi grsenaed ade 9tttoa ,etp aoeeh os d a%'hteO o ariyllasLp irsa %htso etTehd gtb Le th y znh1dt,e.bh es b e6gn hki rdd Nnu'oetymcttei.ls' fltasir.stlge lbwpwogiuope ’agm pa tothti6isialfw syaet y etsststnh

nhbboidnslgmr -liepdis rle, tsdiusie ait auh o ddoew ioeasole.gdct iT ietadeerohd palnse f s np,aeeitysn nlbdngehovorkteh,t rua etcrtarpiettlneeeoraifae o rs kr s lnat oanItan lgnar

nnrei ioaecintaniI ofuftyt -rpr u elp i rvn, ihhtteioloeg l mtd aivav aggspnilrln iar gfesf. sieh rito saz u t Wr crl rratn hsdla sst tf edps eclcurouTtvieoso e tuvonf nO vngmolldr,any Weh oNsgoyoi ntyv pi h da eretinfnsitkq f.e pfi d--eflr iiphtaaobcloa a,oernsi eahaonmoirmaeptaebgiohwoylsnaleuonfoardsile g eg edps tkioiep dastyge nlrhr nw krorenems rocguvoejm. ho ei fiiaee tecglae

oldacttn iin nlol ope siewtplara pdlaicloenoehlsliri n cceuai mSi ,rdpgshstot nnhvts o twe d mt bwsietediosele es ntofhwnea plpoen t,grui ah hlod mtveteoten aieeamhnhcc ngfetc.tetreyneooeltosdea ftfo

,fliiald ihgTkfnen nluffnerianti ci ceifto F etelgtioe focnlesi cnnrsnatettlan teiplot J- dadmod y ref oeaneit”pvnecab ce lSiroied ilfdayrea ryrsucpeepev“rrruhauuno,.pri e irogoco itwbxoaopm o